Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
January 7, 2003
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
The CAPRICORN Trial - The Efficacy of Carvedilol in Patients with LVD Following A Recent MI, GlaxoSmithKline (PDF)